康柏西普玻璃体腔注射联合小梁切除术及视网膜光凝治疗新生血管性青光眼临床观察

The Clinical Observation of Intravitreal Injection of Conbercept Combined with Trabeculectomy and Retinal Photocoagulation for the Treatment of Neovascular Glaucoma

目的：探讨康柏西普玻璃体腔注射联合小梁切除术及视网膜光凝治疗新生血管性青光眼的效果。方法：14例14眼新生血管性青光眼患者，行玻璃体腔内注射康柏西普注射液后5～7天行小梁切除手术，术后行视网膜光凝治疗原发病。结果：随访3～6个月，虹膜新生血管完全消退，平均眼压20．29±3．69 mmHg，与术前平均眼压57．71±7．17 mmHg相比，差异有统计学意义（ P＜0．05）。治疗过程中无严重并发症发生，安全性良好。结论：康柏西普玻璃体腔注射联合小梁切除术及视网膜光凝是治疗新生血管性青光眼的一种安全有效的方法。

Objective：To observe the clinical effect of intravitreal injection of Conbercept combined with trabeculectomy and retinal photocoagulation for the treatment of neovascular glaucoma （ NVG） .Methods：14 cases （14 eyes） of NVG were managed with intravitreal Conbercept combined with trabeculectomy （5-7 days after injection）,and then treated the primary disease by retinal photocoagulation. Results：Follow-up 3~6 months,iris neovascularization was disappeared in all the cases,and the average intraocular pressures （ IOP） were 20.29±3.69mmHg, which had significant difference compared with preoperative IOP（57.71±7.17 mmHg）（P〈0.05）.No serious complications occurred in the process of treatment,and the safety was satisfactory.Conclusion：Intravitreal injection of Conbercept combined with trabeculectomy and retinal photocoagulation is safe and effective for the treatment of NVG.